Form 4: MIRA CEO Aminov Granted 83,500 Vested Restricted Stock Units

MIRA Pharmaceuticals CEO Erez Aminov received a grant of 83,500 fully vested restricted stock units, convertible to common stock.

Summary

• Erez Aminov, Chief Executive Officer, Director, and 10% Owner of MIRA Pharmaceuticals, Inc. (MIRA), was granted 83,500 Restricted Stock Units (RSUs).
• The RSUs were granted on March 30, 2026, and fully vested on the same date.
• Each RSU represents the right to receive one share of MIRA's common stock.
• Following this transaction, Aminov directly beneficially owns 83,500 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting increased insider ownership and alignment of the CEO's interests with shareholders, which is generally seen favorably.

Positives

• The CEO's direct acquisition of 83,500 fully vested Restricted Stock Units aligns his interests with shareholders.
• The immediate vesting of the RSUs indicates a strong commitment and immediate ownership stake in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a report of a historical insider transaction.

Industry Context

StockSavvy.ai notes that insider grants of restricted stock units are a common form of executive compensation, often used to align management incentives with long-term shareholder value. The immediate vesting suggests a direct and immediate increase in the CEO's equity stake.

Comparison to Industry Standards

• StockSavvy.ai observes that grants of restricted stock units to executive officers are a standard practice across the pharmaceutical industry and broader public markets.
• While the specific number of units (83,500) is company-specific, the mechanism of compensation is consistent with peers.
• For instance, similar RSU grants are common at companies like Pfizer, Moderna, and Johnson & Johnson, where executive compensation packages frequently include equity components to incentivize performance and retention.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with shareholder value through direct equity ownership.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event where the CEO received restricted stock units. While it increases insider ownership, it does not present new fundamental information that would warrant a change in investment recommendation. It's a standard practice to align management incentives, thus a 'hold' recommendation is appropriate as it doesn't significantly alter the investment thesis.

Keywords

MIRA Pharmaceuticals, MIRA, Erez Aminov, Restricted Stock Units, RSU, Insider Transaction, CEO, Stock Grant, Beneficial Ownership, Form 4